Shionogi said on July 10 that it will launch a voluntary redundancy program targeting around 200 non-managerial employees aged 50 and older. The applicants will be leaving the company at the end of October. Eligible for the program are 50-plus-year-old…
To read the full story
Related Article
- Shionogi Workforce Down 341 after Voluntary Buyout Program
June 24, 2024
- 301 Employees Apply for Shionogi’s Voluntary Buyout Program
November 1, 2023
BUSINESS
- CSL Behring Japan President Yoshida to Step Down
June 8, 2026
- Japan Approves Oncolys’ Telomelysin for Esophageal Cancer
June 8, 2026
- Takeda Swings to Loss after Booking Amitiza Litigation Charge
June 8, 2026
- GNI to Acquire Ayumi Pharma in 44.8 Billion Yen Deal
June 8, 2026
- Shionogi Releases Japan’s First Therapy App for Pediatric ADHD
June 8, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





